Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Journal of Cardiology

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijcard.2018.01.077PMID 29544929
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correction to: Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy‑associated cardiomyopathy

  2020cited by this paper
• Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure

  2019cited by this paper
• Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

  2019cited by this paper
• Sacubitril/valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function

  2019cited by this paper
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2016cited by this paper
• Structure of neprilysin in complex with the active metabolite of sacubitril

  2016cited by this paper
• Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

  2016cited by this paper
• LCZ696, an angiotensin receptor–neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin‐induced diabetic mice

  2016cited by this paper
• Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis.

  2015cited by this paper
• Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy

  2015cited by this paper
• Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

  2015cited by this paper
• Effects of angiotensin-converting enzyme inhibition and bradykinin peptides in rats with myocardial infarction.

  2015cited by this paper
• Effects of PP1-12, a Novel Protein Phosphatase-1 Inhibitor, on Ventricular Function and Remodeling After Myocardial Infarction in Rats

  2014cited by this paper
• Atrial Natriuretic Peptide Affects Cardiac Remodeling, Function, Heart Failure, and Survival in a Mouse Model of Dilated Cardiomyopathy

  2014cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• The Uremic Toxin Adsorbent AST-120 Abrogates Cardiorenal Injury Following Myocardial Infarction

  2013cited by this paper
• Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.

  2013cited by this paper
• Subtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction: implications for cardiorenal syndrome.

  2013cited by this paper
• The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

  2012cited by this paper
• Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides

  2011cited by this paper
• Decreased metalloprotease 9 induction, cardiac fibrosis, and higher autophagy after pressure overload in mice lacking the transcriptional regulator p8.

  2011cited by this paper
• Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females.

  2010cited by this paper
• Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

  2010cited by this paper
• TIMP2 Deficiency Accelerates Adverse Post–Myocardial Infarction Remodeling Because of Enhanced MT1-MMP Activity Despite Lack of MMP2 Activation

  2010cited by this paper
• Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association

  2009cited by this paper
• Long-Term but Not Short-Term p38 Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Cardiac Remodeling Post-Myocardial Infarction

  2008cited by this paper
• The role of natriuretic peptides in cardioprotection.

  2006cited by this paper
• Mechanisms of atrial natriuretic peptide secretion from the atrium.

  2005cited by this paper
• Trends in heart failure incidence and survival in a community-based population.

  2004cited by this paper
• Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.

  2003cited by this paper
• Role of the natriuretic peptide system in cardiorenal protection.

  2003cited by this paper
• Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP.

  2003cited by this paper
• Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

  2002cited by this paper
• Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.

  2001cited by this paper
• Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart.

  2001cited by this paper
• MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition.

  2000cited by this paper
• Valsartan and coronary haemodynamics in early post‐myocardial infarction in rats

  1999cited by this paper
• Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction.

  1998cited by this paper
• Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction.

  1996cited by this paper
• Rat infarct model of myocardial infarction and heart failure.

  1995cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Relationship between decrease in afterload and beneficial effects of ACE inhibitors in experimental cardiac hypertrophy and congestive heart failure.

  1990cited by this paper

• Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations)

  2025cites this paper
• Sacubitril-Valsartan in Cancer Therapy-Induced Heart Failure: A Systematic Review and Meta-Analysis of Functional and Hemodynamic Parameters.

  2025cites this paper
• Real-world comparative effectiveness of angiotensin-neprilysin inhibition versus angiotensin receptor blockers in acute myocardial infarction.

  2025cites this paper
• Renal Denervation Ameliorates Cardiomyocyte Apoptosis in Myocardial Ischemia–Reperfusion Injury Through Regulating Mitochondria–Endoplasmic Reticulum Contact

  2024cites this paper
• Rat Models of Cardiorenal Syndrome and Methods for Functional Assessment.

  2024cites this paper
• Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.

  2024cites this paper
• Enhancing ventricular remodeling and cardiac function in post-acute myocardial infarction with sacubitril/valsartan.

  2024cites this paper
• Sacubitril/valsartan alleviates sepsis-induced myocardial injury in rats via dual angiotensin receptor-neprilysin inhibition and modulation of inflammasome/caspase 1/IL1β pathway.

  2024cites this paper
• The history and mystery of sacubitril/valsartan: From clinical trial to the real world

  2023cites this paper
• Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis

  2023cites this paper
• Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction

  2023cites this paper
• Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity

  2023influential citation
• Bioinformatics and experimental studies jointly reveal that Sacubitril Valsartan improves myocardial oxidative stress and inflammation by regulating the MAPK signaling pathway to treat chemotherapy related cardiotoxicity.

  2023cites this paper
• Research Progress on the Application of Sacubitril/Valsartan to Heart Failure

  2023cites this paper
• The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

  2023cites this paper
• Corrigendum to "Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice" [Biomed. Pharmacother. 133 (2021) 110824].

  2022cites this paper
• Molecular mechanisms of sacubitril/valsartan in cardiac remodeling

  2022cites this paper
• Sacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance

  2022cites this paper
• Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System

  2022cites this paper
• Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy.

  2022cites this paper
• Heart Failure with Improved Ejection Fraction: Insight into the Variable Nature of Left Ventricular Systolic Function

  2022cites this paper
• Short-term efficacy of angiotensin receptor-neprilysin inhibitor treatment in patients with ST-segment elevation myocardial infarction with reduced ejection fraction after primary percutaneous coronary intervention: a propensity score matching study

  2022influential citation
• Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy

  2022cites this paper
• Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis

  2022cites this paper
• Aryl Hydrocarbon Receptor Inhibition Restores Indoxyl Sulfate-Mediated Endothelial Dysfunction in Rat Aortic Rings

  2022cites this paper
• The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats

  2022cites this paper
• Non-transmural myocardial infarction associated with regional contractile function is an independent predictor of positive outcome: an integrated approach to myocardial viability

  2021cites this paper
• Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.

  2021cites this paper
• Renal Denervation Ameliorates Cardiomyocyte Apoptosis in Myocardial Ischemia-reperfusion Injury

  2021cites this paper
• Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction

  2021influential citation
• Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-β1/Smads Pathway

  2021cites this paper
• Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3-induced pyroptosis via the TAK1/JNK signaling pathway

  2021cites this paper
• Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts

  2021cites this paper
• Rationale and design of a multi‐center, prospective randomized controlled trial on the effects of sacubitril–valsartan versus enalapril on left ventricular remodeling in ST‐elevation myocardial infarction: The PERI‐STEMI study

  2021influential citation
• Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial.

  2021cites this paper
• Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis

  2020cites this paper
• Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity

  2020cites this paper
• RAS inhibition in resident fibroblast biology.

  2020cites this paper
• Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling

  2020cites this paper
• Increasing heart vascularisation after myocardial infarction using brain natriuretic peptide stimulation of endothelial and WT1+ epicardial cells

  2020cites this paper
• Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.

  2020cites this paper
• Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction

  2020cites this paper
• Increasing heart vascularisation after myocardial infarction using brain natriuretic peptide stimulation of endothelial and WT1+ epicardium-derived cells

  2020cites this paper
• Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR‐181a in a Rodent Chronic Myocardial Infarction Model

  2020cites this paper
• Correction to: Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy‑associated cardiomyopathy

  2020cites this paper
• Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome.

  2020cites this paper
• Genistein reverses isoproterenol-induced cardiac hypertrophy by regulating miR-451/TIMP2.

  2019cites this paper
• Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy-associated cardiomyopathy

  2019cites this paper
• Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats.

  2019cites this paper
• Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

  2019cites this paper
• Effects of Angiotensin Receptor Neprilysin Inhibitors on Inducibility of Ventricular Arrhythmias in Rats with Ischemic Cardiomyopathy.

  2019cites this paper
• Renal denervation ameliorates post-infarction cardiac remodeling in rats through dual regulation of oxidative stress in the heart and brain.

  2019cites this paper
• Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure

  2019cites this paper
• Cardioprotective effects of the total flavonoids of Polygonum cuspidatum Sieb. et Zucc. Root extract on experimental myocardial infarction in mice

  2019cites this paper
• Sacubitril/valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function

  2019cites this paper
• Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety

  2018cites this paper